SUMMARY:Most sinonasal lymphomas have a restricted killer immunoglobulin-like receptor (KIR) repertoire without a monoclonal T-cell receptor-␥ (TCR-␥) rearrangement, implying an NK lineage. However, the lineage assignment of sinonasal lymphoma with a monoclonal TCR-␥ rearrangement is unclear because of its mixed NK/T phenotype. The possibility of a mixed NK/T lineage arises with the discovery of T cells with NK features, such as KIR ϩ T cells or V␣24 ϩ NKT cells. The former might transform into a T-cell lymphoma with both a monoclonal TCR-␥ rearrangement and a restricted KIR repertoire; the latter might give rise to a T-cell lymphoma with a monoclonal V␣24 rearrangement and possibly a restricted KIR repertoire. To identify such mixed-lineage lymphomas, we undertook a survey of 15 consecutive sinonasal lymphomas and found six with both a restricted KIR repertoire and a monoclonal TCR-␥ rearrangement, consistent with KIR ϩ T-cell lymphomas. Among these six cases, four female CD56Ϫ cases constituted a distinct group with a better prognosis than the rest of the male cases of sinonasal lymphomas. None of the six cases had a monoclonal V␣24 repertoire, thus excluding a derivation from NKT cells. The predominance of KIR ϩ T cells that normally function in chronic viral infections over V␣24 ϩ NKT cells that typically recognize glycolipid antigens is consistent with the known association of Epstein-Barr virus infection with sinonasal lymphoma. The demonstration of mixed lineage in a mature lymphoid neoplasm is unusual and echoes the World Health Organization classification that placed NK-cell and T-cell lymphomas in a mixed group. (Lab Invest 2003, 83:55-64).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.